Norway's Heroin Program Isn't a Cure — It's the Ceasefire That Makes Recovery Possible

Four years in, Norway’s heroin-assisted treatment program has an answer nobody on either side of this fight really wanted: it works, and it isn’t enough.

The final evaluation from the Norwegian Centre for Addiction Research (SERAF) tracked people with the most severe, longest-running heroin dependence in Oslo and Bergen — people every other treatment had already failed — through four years of twice-daily supervised doses of pharmaceutical-grade heroin. The results, reported in July: less street heroin use, less self-reported crime, moderate gains in health and quality of life, and — this is the part nobody’s arguing about loud enough — 88% of the people who eventually left the program moved on to standard opioid agonist therapy, methadone or buprenorphine, the medication that actually lets you build a life instead of showing up twice a day.

Supervised heroin isn’t a cure — it’s a ceasefire long enough for real treatment to start working.

Both sides of this fight keep arguing about it like it’s supposed to be the finish line. Here’s what a ceasefire buys that a moral argument can’t. Dependence is your body quietly resetting its own baseline around a drug being present, so that not having it registers as an emergency — that’s withdrawal, your nervous system protesting the absence, and it is not weakness, it’s neurons that adapted doing the only thing they know how to do. Craving is your brain running a background process that hijacks the rest of your decision-making toward getting well, whether you authorized it or not — not “wanting it,” a computation you can’t out-argue with willpower. If you’ve been there, you know the twice-daily math HAT is built to interrupt: is today the day I get sick trying to score, or sick because I couldn’t. Take that math off the table and the part of your brain that was running triage all day is suddenly free to do something else — sit through an appointment, hold a job interview, stay in a room with a counselor for forty-five minutes without your skin crawling.

That’s why the RAND Corporation’s own review found supervised injection carries real risk — more adverse events than methadone, people still mixing in benzodiazepines and meth on top — and why a September 9 critique is right that HAT shouldn’t be sold as a broad fix for a national crisis. It also shouldn’t get dismissed as a failure, because it isn’t one. Norway’s own researchers aren’t calling for national rollout either — they’re calling it a narrow, expensive bridge for the people standard treatment already lost, and recommending it stay open exactly where it is. That’s not insanity and it’s not a miracle. It’s triage, and triage that gets 88% of the sickest people in the country onto treatment that sticks is doing its job.

You don’t owe anyone a redemption arc to deserve not dying between now and whenever you’re ready. Norway just spent four years proving that keeping people alive and steady long enough to want more counts as treatment, not enabling. Build the bridge. Argue about the destination later.